Moreover, inflammation-induced elevation of fibroblast growth factor 23 (FGF23)—often heightened in CKD—facilitates erythrocyte apoptosis by suppressing EPO response and raising intracellular ROS levels (Czaya and Faul, 2019; Coe et al., 2014). This evidence concerns the gene EPO and chronic kidney disease.